Study guide

13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma

Professional and Linguistic Assessments Board Part 1 PLAB 1

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PLAB 1 Exam

2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies

1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies

3 Chapter 2: Cardiovascular Medicine & Vascular Disorders

2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease

4 Chapter 3: Respiratory Medicine

3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure

5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery

4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD

6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance

5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies

7 Chapter 6: Endocrinology & Metabolic Medicine

6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease

8 Chapter 7: Neurology & Neurosciences

7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders

9 Chapter 8: Psychiatry & Mental Health

8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health

10 Chapter 9: Obstetrics, Gynaecology & Sexual Health

9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence

11 Chapter 10: Paediatrics & Child Health

10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems

12 Chapter 11: Musculoskeletal Medicine & Rheumatology

11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders

13 Chapter 12: Dermatology, ENT & Ophthalmology

12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer

14 Chapter 13: Haematology, Oncology & Palliative Care

13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral

15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology

14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship

16 Chapter 15: Medical Ethics, Law & UK Clinical Practice

15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse

17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention

18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging

17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays

13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma

Key Takeaways Explain This Topic AI

Acute leukaemias present with rapid-onset bone marrow failure (anaemia, neutropenic infections, thrombocytopenic bleeding) and >20% blasts; APML with t(15;17) is an oncological emergency requiring immediate All-Trans Retinoic Acid (ATRA) to abort fatal DIC.

CML is driven by the Philadelphia chromosome t(9;22) creating the constitutively active BCR-ABL1 tyrosine kinase, successfully targeted by imatinib; CLL is an indolent B-cell leukaemia characterized by smudge/smear cells and autoimmune cytopenias.

Hodgkin lymphoma features Reed-Sternberg giant cells with a bimodal age distribution and contiguous nodal spread; excisional lymph node biopsy is the mandatory gold standard for diagnosing lymphomas.

Multiple myeloma is characterized by the CRAB criteria (Hypercalcaemia, Renal impairment, Normocytic anaemia, Bone lytic lesions); diagnosis is confirmed by serum protein electrophoresis (monoclonal M-protein spike) and serum free light chains.

Last updated: October 2026

Haematological Malignancies: Leukaemias, Lymphomas & Myeloma

Haematological malignancies encompass a broad spectrum of neoplastic proliferations arising from hematopoietic stem cells, myeloid or lymphoid progenitors, and differentiated lymphoid or plasma cell lineages. Clinical investigation and urgent referral pathways follow NICE guidelines (NG12: Suspected cancer recognition and referral) and British Society for Haematology standards.

1. Acute Leukaemias

Acute leukaemias are characterised by the rapid, clonal proliferation of immature, non-functional hematopoietic blast cells arrested in early differentiation. Blasts accumulate in the bone marrow (>20% marrow cellularity) and spill into the peripheral blood, displacing normal haematopoiesis and causing fulminant bone marrow failure :

Anaemia: Severe lethargy, exertional dyspnoea, pallor, and cardiac ischaemia.

Neutropenia: Recurrent, severe, or opportunistic bacterial and fungal infections; fever.

Thrombocytopenia: Petechiae, spontaneous ecchymoses, epistaxis, and mucosal bleeding.

Acute Myeloid Leukaemia (AML)

Epidemiology: Predominantly an illness of older adults (median age at diagnosis ~68 years).

Diagnostic Hallmarks: Peripheral blood film and bone marrow aspirate show large, granular myeloblasts. The presence of Auer rods —clumped crystalline aggregates of lysosomal myeloperoxidase visible as pink/red linear needle-like cytoplasmic inclusions—is pathognomonic of AML.

Acute Promyelocytic Leukaemia (APML / AML M3):

Cytogenetics: Pathognomonic reciprocal translocation t(15;17)(q24;q21) , which fuses the promyelocytic leukaemia ( PML ) gene on chromosome 15 to the retinoic acid receptor alpha ( RARA ) gene on chromosome 17, blocking myeloid differentiation at the promyelocyte stage.

Medical Emergency: Promyelocytes contain abundant azurophilic granules rich in tissue factor and annexin II. Cell breakdown triggers fulminant, catastrophic Disseminated Intravascular Coagulation (DIC) , with high risks of early intracranial or pulmonary haemorrhage.

Immediate Therapy: Immediately initiate All-Trans Retinoic Acid (ATRA / Tretinoin) alongside arsenic trioxide (ATO) the moment APML is clinically or morphologically suspected, without waiting for cytogenetic or PCR confirmation . ATRA forces malignant promyelocytes to differentiate into mature neutrophils, terminating the procoagulant crisis.

Acute Lymphoblastic Leukaemia (ALL)

Epidemiology: The commonest childhood malignancy, with a peak incidence between 2 and 5 years of age ; a second smaller incidence peak occurs in adults over 60 years.

Clinical Presentation: Bone and joint pain (often presenting as a limp or refusal to bear weight due to leukaemic marrow expansion and periosteal infiltration), pallor, bruising, high fevers, generalized painless lymphadenopathy, and prominent hepatosplenomegaly .

Sanctuary Sites: Leukaemic lymphoblasts characteristically infiltrate anatomical sanctuary sites shielded by biological barriers, namely the Central Nervous System (CNS) and the testes (manifesting as painless, stony-hard testicular enlargement).

Management: Multi-agent systemic induction chemotherapy followed by prolonged maintenance therapy. Intrathecal chemotherapy (methotrexate and cytarabine) is mandatory for CNS prophylaxis and treatment. Childhood ALL achieves cure rates exceeding 90%.

  • 2. Chronic Leukaemias
  • Chronic Myeloid Leukaemia (CML)

Pathophysiology: A clonal myeloproliferative neoplasm characterized by the unregulated proliferation of mature and maturing granulocytic lineages. Driven by the Philadelphia chromosome , an acquired reciprocal translocation t(9;22)(q34;q11) .

Molecular Genetics: Translocates the ABL1 proto-oncogene from chromosome 9 to the BCR locus on chromosome 22, generating the BCR-ABL1 fusion gene . This encodes a constitutively active p210 tyrosine kinase that drives autonomous cellular proliferation and suppresses apoptosis.

Clinical Presentation: Often discovered incidentally on routine full blood count; symptomatic patients present with weight loss, nocturnal hyperhidrosis, fatigue, gout (hyperuricaemia from rapid purine turnover), and symptoms of massive splenomegaly (early satiety, dragging left upper quadrant fullness).

Laboratory Profile: Profound leukocytosis (frequently 50–300 x 10^9/L) displaying the entire spectrum of granulocytic differentiation (myeloblasts <10%, promyelocytes, myelocytes, metamyelocytes, band forms, and mature neutrophils). Markedly elevated basophil and eosinophil counts.

Targeted Therapy: First-line treatment revolutionized survival through oral Tyrosine Kinase Inhibitors (TKIs) , primarily Imatinib (first-generation) or second-generation TKIs ( Dasatinib , Nilotinib ). TKIs competitively bind the ATP-binding pocket of the BCR-ABL1 kinase, restoring normal haematopoiesis and achieving near-normal life expectancy.

Chronic Lymphocytic Leukaemia (CLL)

Pathophysiology: The most prevalent leukaemia in adults in Western countries; median age at diagnosis ~70 years. Arises from a clonal expansion of incompetent, mature-appearing B-lymphocytes co-expressing CD5, CD19, and CD23 .

Clinical Presentation: Over 70% of patients are entirely asymptomatic at presentation, identified via an incidental finding of marked absolute lymphocytosis (>5 x 10^9/L) . Symptomatic patients manifest with painless, non-tender, symmetrical, rubbery generalized lymphadenopathy, hepatosplenomegaly, and fatigue.

Blood Film: Packed with small, monomorphic mature lymphocytes alongside fragile, disrupted cellular remnants known as "smear cells" or "smudge cells" .

Immune Complications:

Hypogammaglobulinaemia: Progressive failure of normal antibody synthesis leads to recurrent severe encapsulating bacterial respiratory tract infections.

Autoimmune Cytopenias: Autoimmune haemolytic anaemia (warm AIHA, DAT positive) occurs in 10%–15%, as does immune thrombocytopenia (ITP).

Richter's Transformation: Acute transformation (~5%–10% of cases) into an aggressive, high-grade Diffuse Large B-Cell Lymphoma (DLBCL) , heralded by rapid asymmetric lymph node enlargement, sudden onset B symptoms, and rising LDH.

Management: Early, asymptomatic CLL is managed with a "watch and wait" surveillance strategy, as early cytotoxic intervention yields no survival benefit. Treatment is indicated only for active, symptomatic disease (B symptoms, progressive marrow failure, massive lymphadenopathy/splenomegaly), using targeted agents such as Bruton's tyrosine kinase inhibitors ( Ibrutinib , Acalabrutinib ) or BCL-2 antagonists ( Venetoclax ) in combination with anti-CD20 monoclonal antibodies ( Obinutuzumab , Rituximab ).

Leukaemia Type Typical Patient Demographics Key Diagnostic Findings First-Line Management Strategy

AML Older adults (median ~68 years) >20% myeloblasts; Auer rods pathognomonic Intensive multi-agent chemotherapy; ATRA + ATO for APML t(15;17)

ALL Children (peak 2–5 years) >20% lymphoblasts; bone pain, organomegaly, sanctuary spread Remission induction chemotherapy + mandatory intrathecal prophylaxis

CML Adults (40–60 years) t(9;22) BCR-ABL1 ; massive splenomegaly; full granulocytic spectrum Oral Tyrosine Kinase Inhibitors ( Imatinib , Dasatinib)

CLL Elderly (>65 years) Mature lymphocytosis (>5 x 10^9/L); smear/smudge cells ; CD5+ B cells "Watch and wait" if asymptomatic; BTK inhibitors (Ibrutinib) or Venetoclax

3. Malignant Lymphomas

Lymphomas represent primary neoplastic proliferations of lymphoid tissue. Clinical presentation typically features painless, rubbery, discrete, non-tender lymphadenopathy (most commonly cervical >70%, followed by supraclavicular, axillary, and inguinal nodes). Systemic "B symptoms" are defined as:

  • Unexplained persistent fever (>38.0°C)
  • Drenching night sweats (requiring changing nightclothes/bedding)
  • Unintentional weight loss (>10% of baseline body weight over the preceding 6 months)

Important

Diagnostic Gold Standard: The definitive diagnosis of lymphoma requires an excisional lymph node biopsy (or whole-node surgical biopsy). Fine-needle aspiration (FNA) is strictly inadequate because it only provides cytological aspirates without preserving nodal histological architecture, preventing accurate WHO subtyping and grading.

Hodgkin Lymphoma (HL)

Pathology: Characterised by neoplastic giant multinucleated cells known as Reed-Sternberg cells (classically displaying a bilobed nucleus with prominent inclusion-like nucleoli resembling "owl's eyes", staining positive for CD15 and CD30 , negative for CD45 and CD20), set against a reactive inflammatory background.

Epidemiology: Distinct bimodal age distribution , with the primary peak in young adults (20–30 years) and a secondary peak in older adults (>60 years).

Clinical Presentation: Orderly, contiguous anatomical spread along contiguous nodal chains; extranodal involvement is rare at presentation. A classic, specific symptom is alcohol-induced lymph node pain (immediate severe pain in involved nodes following alcohol ingestion). Pel-Ebstein fevers (cyclical fevers fluctuating over days) are occasionally observed.

Prognosis & Therapy: Highly curable (>85% 5-year overall survival) using multi-agent chemotherapy, historically the ABVD regimen (Adriamycin [Doxorubicin], Bleomycin, Vinblastine, Dacarbazine) with or without involved-site radiotherapy. Long-term survivorship surveillance is critical due to treatment-related second malignancies (e.g. breast cancer in young women irradiated to the chest) and cardiopulmonary toxicity (bleomycin pulmonary fibrosis, anthracycline cardiomyopathy).

Non-Hodgkin Lymphoma (NHL)

Overview: A diverse group of B-cell (~85%) and T-cell/NK-cell (~15%) malignancies. Characterised by non-contiguous, unpredictable nodal spread and a high propensity for early extranodal disease (gastrointestinal tract [most common extranodal site], bone marrow, liver, skin, CNS).

Diffuse Large B-Cell Lymphoma (DLBCL): The most common NHL (~35%). High-grade, rapidly proliferating, aggressive malignancy. Rapidly enlarging symptomatic nodal mass or extranodal tumor. Curative intent treatment: R-CHOP chemoimmunotherapy (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone).

Follicular Lymphoma: The most common indolent low-grade NHL (~20%). Arises from germinal centre B cells carrying the pathognomonic chromosomal translocation t(14;18)(q32;q21) , which juxtaposes the BCL2 oncogene to the immunoglobulin heavy chain ( IGH ) promoter, causing BCL2 overexpression and inhibiting apoptosis. Indolent, widely disseminated at presentation, typically incurable with conventional chemotherapy; managed with "watch and wait" until symptomatic, then rituximab-based regimens.

4. Multiple Myeloma

Multiple myeloma is a malignant clonal proliferation of plasma cells originating in the bone marrow, accounting for ~10% of haematological cancers (median age at diagnosis ~70 years). The neoplastic plasma cells produce excess amounts of a single monoclonal immunoglobulin (paraprotein, or M-protein )—most commonly IgG (~60%) or IgA (~20%) —alongside monoclonal free light chains (kappa or lambda).

Diagnostic Hallmark: The CRAB Criteria

Symptomatic, end-organ damaging multiple myeloma is defined by bone marrow clonal plasma cells ≥10% (or biopsy-proven plasmacytoma) in the presence of one or more CRAB criteria :

C — Hypercalcaemia (Serum Calcium >2.75 mmol/L or >0.25 mmol/L above normal): Driven by neoplastic plasma cell production of osteoclast-activating factors (RANKL, MIP-1 alpha) and suppression of osteoblasts (DKK-1), resulting in severe, uncoupled osteolysis. Manifests with polydipsia, polyuria, constipation, confusion, and shortened QT interval.

R — Renal Impairment (Serum Creatinine >177 umol/L or CrCl <40 mL/min): Primarily caused by light chain cast nephropathy ("myeloma kidney") : excess circulating free light chains overwhelm proximal tubular endocytic capacity, precipitate with Tamm-Horsfall mucoprotein in distal tubules, and form obstructive, highly toxic tubular casts. Dehydration, hypercalcaemia, and concurrent NSAID use exacerbate acute kidney injury.

A — Normocytic Normochromic Anaemia (Hb <100 g/L or >20 g/L below normal): Secondary to leukaemic plasma cell replacement of hematopoietic bone marrow niches, cytokine-mediated suppression of erythropoiesis, and relative erythropoietin deficiency from renal disease.

B — Bone Lesions (≥1 Osteolytic Lesion): Punched-out, well-demarcated osteolytic lesions without surrounding reactive osteoblastic sclerosis visible on skeletal surveys, whole-body low-dose CT, or MRI. Causes severe, persistent bone pain (particularly in the lumbar spine, ribs, and pelvis), vertebral compression fractures, spinal cord compression, and pathological fractures.

Diagnostic Laboratory Workup

Serum & Urine Protein Electrophoresis (SPEP & UPEP): Demonstrates a sharp, narrow monoclonal M-protein spike in the gamma globulin region. Urine electrophoresis detects Bence Jones proteinuria (monoclonal free light chains excreted into urine).

Serum Free Light Chain (sFLC) Assay: Quantifies circulating free kappa and lambda chains, showing a pathologically skewed kappa/lambda ratio (>100 or <0.01).

Peripheral Blood Film: Shows prominent rouleaux formation (erythrocytes stacked like coins, driven by high concentrations of positively charged paraprotein neutralizing the negative zeta potential of red cells). Background erythrocyte sedimentation rate (ESR) is markedly elevated (frequently >100 mm/h).

Bone Marrow Aspirate & Trephine Biopsy: Confirms infiltration by ≥10% clonal, atypical plasma cells (clock-face chromatin, abundant basophilic cytoplasm, eccentric nucleus).

Treatment Principles

Induction Triplet Regimen: Proteasome inhibitor ( Bortezomib ) + immunomodulatory drug ( Lenalidomide ) + high-dose corticosteroid ( Dexamethasone ) [the VRd regimen].

Consolidation: Eligible, fit patients under 70 years undergo high-dose melphalan conditioning followed by Autologous Stem Cell Transplantation (ASCT) .

Supportive Skeletal & Renal Protection: All patients with active myeloma require monthly intravenous bisphosphonates (e.g. Zoledronic acid ) to inhibit osteoclast resorption, reduce pathological fractures, and control hypercalcaemia. Vigorous hydration protects renal tubular function.

Loading diagram... Clinical Diagnostic Approach to Leukaemias and Lymphomas